Nothing Special   »   [go: up one dir, main page]

DK3356313T3 - 2-perfluorhexyloktan til oftalmisk indgivelse - Google Patents

2-perfluorhexyloktan til oftalmisk indgivelse Download PDF

Info

Publication number
DK3356313T3
DK3356313T3 DK16775673.3T DK16775673T DK3356313T3 DK 3356313 T3 DK3356313 T3 DK 3356313T3 DK 16775673 T DK16775673 T DK 16775673T DK 3356313 T3 DK3356313 T3 DK 3356313T3
Authority
DK
Denmark
Prior art keywords
perfluorohexyloctane
ophthalmic administration
ophthalmic
administration
Prior art date
Application number
DK16775673.3T
Other languages
English (en)
Inventor
Dieter Scherer
Ralf Grillenberger
Frank LÖSCHER
Hartmut Voss
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Application granted granted Critical
Publication of DK3356313T3 publication Critical patent/DK3356313T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
    • C07C17/266—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16775673.3T 2015-09-30 2016-09-29 2-perfluorhexyloktan til oftalmisk indgivelse DK3356313T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15187760 2015-09-30
EP15192429 2015-10-30
PCT/EP2016/073262 WO2017055453A1 (en) 2015-09-30 2016-09-29 Semifluorinated compounds for ophthalmic administration

Publications (1)

Publication Number Publication Date
DK3356313T3 true DK3356313T3 (da) 2020-07-20

Family

ID=57068093

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20172665.0T DK3722274T3 (da) 2015-09-30 2016-09-29 2-perfluorbutylpentan til oftalmisk indgivelse
DK16775673.3T DK3356313T3 (da) 2015-09-30 2016-09-29 2-perfluorhexyloktan til oftalmisk indgivelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20172665.0T DK3722274T3 (da) 2015-09-30 2016-09-29 2-perfluorbutylpentan til oftalmisk indgivelse

Country Status (15)

Country Link
US (2) US11154513B2 (da)
EP (3) EP3722274B1 (da)
JP (2) JP6642935B2 (da)
KR (2) KR102584063B1 (da)
CN (4) CN108349855B (da)
AU (3) AU2016329261B2 (da)
CA (1) CA2998269C (da)
DE (1) DE202016008739U1 (da)
DK (2) DK3722274T3 (da)
ES (2) ES2803248T3 (da)
HK (1) HK1257182A1 (da)
MX (2) MX2020001408A (da)
PL (2) PL3356313T3 (da)
PT (1) PT3356313T (da)
WO (1) WO2017055453A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US10130707B2 (en) 2011-05-25 2018-11-20 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
ES2770398T3 (es) 2012-09-12 2020-07-01 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados
PT3181119T (pt) 2012-09-12 2019-10-18 Novaliq Gmbh Composições de alcano semiflourado para utilização no tratamento de queratoconjuntivite seca
AU2014295052B2 (en) 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
PT3356313T (pt) * 2015-09-30 2020-07-13 Novaliq Gmbh 2-perfluoro-hexiloctano para administração oftálmica
EP3355990B1 (en) 2015-09-30 2019-06-12 Novaliq GmbH Semifluorinated compounds and their compositions
EP3442480B1 (en) 2016-06-23 2019-10-02 Novaliq GmbH Topical administration method
CN116172987A (zh) 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
JP2020535156A (ja) 2017-09-27 2020-12-03 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) * 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (da) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DK0983037T3 (da) 1998-02-09 2003-09-01 Macrochem Corp Fungicid neglelak
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
PT1666026E (pt) 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
RU2302857C2 (ru) 2001-09-04 2007-07-20 Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель Способ и пластырь для профилактики и/или лечения дисфункции и/или нарушения роста ногтей
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ES2541488T3 (es) 2003-08-25 2015-07-21 Foamix Pharmaceuticals Ltd. Espuma farmacéutica penetrante
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
US20050175541A1 (en) 2003-11-19 2005-08-11 Lanza Gregory M. Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CA2563544A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
EP1763336A1 (en) 2004-06-08 2007-03-21 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
JP2009503059A (ja) 2005-08-05 2009-01-29 ブハラット セルムズ アンド ヴァクシンズ リミテッド 防腐効果を有する静脈プロポフォールエマルジョン組成物
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
BRPI0714587A2 (pt) 2006-07-25 2013-05-07 Osmotica Corp suluÇço oftÁlmica aquosa e uso da nesna
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
EP2068828A2 (en) 2006-09-29 2009-06-17 SurModics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
JP5569899B2 (ja) 2006-11-28 2014-08-13 ウィスコンシン・アラムナイ・リサーチ・ファウンデーション 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション
EP2089282B1 (en) 2006-12-07 2014-01-08 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PT2110126E (pt) 2008-04-18 2012-02-20 Novaliq Gmbh Utilização inalativa e instilativa de alcanos semifluorados como veículos de substância activa na região intrapulmonar
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
US8809261B2 (en) 2008-10-31 2014-08-19 Elsohly Laboratories, Incorporated Compositions containing delta-9-THC-amino acid esters and process of preparation
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス，インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
WO2010150378A1 (ja) 2009-06-25 2010-12-29 ライオン株式会社 眼科用組成物
PL2387391T3 (pl) 2009-07-24 2017-09-29 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Sposób otrzymywania ciekłej kompozycji stosowalnej w postaci piany na skórę oraz kompozycja do aplikowania miejscowego
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
AU2012204932B2 (en) 2011-01-04 2017-02-23 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
US10130707B2 (en) 2011-05-25 2018-11-20 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
AU2012260788B2 (en) 2011-05-25 2017-01-19 Dermaliq Therapeutics, Inc. Pharmaceutical composition for administration to nails
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
PT3181119T (pt) 2012-09-12 2019-10-18 Novaliq Gmbh Composições de alcano semiflourado para utilização no tratamento de queratoconjuntivite seca
ES2770398T3 (es) * 2012-09-12 2020-07-01 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
AU2014295052B2 (en) 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
WO2015053829A1 (en) 2013-10-09 2015-04-16 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
ES2949040T3 (es) 2014-03-31 2023-09-25 Amcor Rigid Plastics Usa Llc Recipiente de liberación controlada
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
EP3179975B1 (en) 2014-08-13 2024-12-11 University of Florida Research Foundation, Inc. Preservative removal from eye drops
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
PT3356313T (pt) * 2015-09-30 2020-07-13 Novaliq Gmbh 2-perfluoro-hexiloctano para administração oftálmica
EP3355990B1 (en) * 2015-09-30 2019-06-12 Novaliq GmbH Semifluorinated compounds and their compositions
EP3442480B1 (en) 2016-06-23 2019-10-02 Novaliq GmbH Topical administration method
CN116172987A (zh) 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
EP3518921B1 (en) 2016-09-28 2021-08-11 Novaliq GmbH Compositions comprising a cannabinoid receptor binding ligand
BR112019012568A2 (pt) 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco

Also Published As

Publication number Publication date
PL3356313T3 (pl) 2020-11-16
US11154513B2 (en) 2021-10-26
KR20200106097A (ko) 2020-09-10
CN108349855A (zh) 2018-07-31
DE202016008739U1 (de) 2019-04-29
EP4234523A1 (en) 2023-08-30
AU2020205239B2 (en) 2021-10-21
CN108349855B (zh) 2021-07-20
AU2022200366B2 (en) 2023-11-09
JP2020073551A (ja) 2020-05-14
HK1257182A1 (zh) 2019-10-18
EP3356313B1 (en) 2020-05-06
AU2016329261A1 (en) 2018-04-12
AU2016329261B2 (en) 2020-05-07
JP7050741B2 (ja) 2022-04-08
MX2018003781A (es) 2018-09-12
KR102154415B1 (ko) 2020-09-10
CA2998269C (en) 2021-03-23
EP3722274B1 (en) 2023-06-07
AU2022200366A1 (en) 2022-02-17
US20170087101A1 (en) 2017-03-30
JP2018529693A (ja) 2018-10-11
DK3722274T3 (da) 2023-09-11
CN110693825A (zh) 2020-01-17
CN110693825B (zh) 2022-03-08
CN113662928A (zh) 2021-11-19
PL3722274T3 (pl) 2023-12-04
US20210315832A1 (en) 2021-10-14
CN113662929A (zh) 2021-11-19
ES2953837T3 (es) 2023-11-16
EP3356313A1 (en) 2018-08-08
JP6642935B2 (ja) 2020-02-12
KR102584063B1 (ko) 2023-09-27
CA2998269A1 (en) 2017-04-06
WO2017055453A1 (en) 2017-04-06
KR20180059823A (ko) 2018-06-05
AU2020205239A1 (en) 2020-07-30
MX2020001408A (es) 2022-04-13
PT3356313T (pt) 2020-07-13
EP3722274A1 (en) 2020-10-14
AU2020205239B9 (en) 2021-10-28
ES2803248T3 (es) 2021-01-25

Similar Documents

Publication Publication Date Title
DK3356313T3 (da) 2-perfluorhexyloktan til oftalmisk indgivelse
HK1256383A1 (zh) 治療劑
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
EP3374114A4 (en) WORKBENCH
BR112016030368A2 (pt) composição oftálmica
DK3265421T3 (da) Doseringssystem
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
EP3209331C0 (en) EYE SOLUTION
DK3380139T3 (da) Medikamentadministrationsanordning
DK3125898T3 (da) Farmakofor til trail-induktion
DK3171701T3 (da) Infusionsanlæg
DK3283058T3 (da) Ribociclib-tablet
DK3199161T3 (da) Farmaceutisk præparat
EP3437644A4 (en) MEDICINE
DK3230929T3 (da) Forbedringer til tælleranordninger
DK3348260T3 (da) Farmaceutisk tramadol-sammensætning til oftalmisk anvendelse
KR20180084810A (ko) 정제 세트
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
DK3280447T3 (da) Farmaceutiske formuleringer
EP3527216A4 (en) Medicine
DK3349825T3 (da) Lægemiddeladministrationsanordning
DK3349827T3 (da) Lægemiddeladministrationsanordning
EP3395344A4 (en) MEDICINE
EP3406230C0 (en) Cannula